Select region:

Clinical trials located in

Katowice

Katowice city is located in Poland. Currently, 20 clinical trials are being conducted in this city.

Katowice, a city in southern Poland, is the heart of the Upper Silesian Industrial Region. Established in the 19th century, it rapidly grew due to coal mining and steel production. Today, it’s a cultural hub, hosting the renowned Rawa Blues Festival, the largest indoor blues festival in the world. Katowice also surprises with its modernist architecture and green spaces, including the much-loved Silesian Park. The city is a testament to Poland’s industrial heritage and its transformation into a vibrant urban center.

  • CT-EU-00023235

    Investigating efficacy and safety of new therapy in early-stage Parkinson’s disease

    This clinical trial aims to examine BIIB122, a new medication considered to potentially slow down the progression of early-stage Parkinson’s disease in patients aged between 30–80 years old. Participants will undergo treatment with either BIIB122 or a placebo equal in appearance but devoid of actual medicine. The trial’s routine includes a single daily medication intake for a timeframe between 48 and 144 weeks. To evaluate the medication’s efficacy, patients’ symptoms and their impact on everyday life will be observed using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). In addition to this, safety assessment of BIIB122 will be a main focus of the study. The trial treats this as a double-blind study, anonymizing whether a patient takes the BIIB122 drug or a placebo.

    AustriaFranceGermanyItalyNetherlandsPolandSpainUnited Kingdom
  • Exploring the safety of seladelpar in treating primary biliary cholangitis

    This is a long-term study on a drug named seladelpar for people with a liver disease called Primary Biliary Cholangitis (PBC). The main goal is to see if this drug is safe and easy for patients with PBC to use over a long period. A secondary goal is to see if seladelpar can effectively treat PBC and improve the patient’s quality of life. The study will track a few things, like if there are changes in the patient’s liver health which may lead to hospitalization or if the patient’s liver enzymes like alkaline phosphate and bilirubin level normalize or not after taking this drug.

    AustriaBelgiumCzechiaFranceGermanyGreeceHungaryItalyNetherlandsPolandRomaniaSpainUnited Kingdom
  • Study on luspatercept treatment for Myelodysplastic Syndrome

    This study is looking into a medication named Luspatercept and how safe and effective it is for people who have a blood condition known as lower-risk Myelodysplastic Syndrome, or LR-MDS for short. These individuals often need transfusions or have their blood refreshed with new, healthy red blood cells. The drug will be given at its highest approved dose to see what effect it has. This is being done in a controlled and careful way to make sure everything is safe for the participants in the study. People who are taking part in this study have been identified as having a very low to medium risk according to the International Prognostic Scoring System (IPSS-R). This means their disease isnt considered high-risk, which makes them suitable candidates for this research. The study is open-label, meaning everybody knows what is in the drug they are getting.

    BelgiumCzechiaFranceGermanyItalyPolandSpain
  • A comprehensive evaluation of retatrutide in obesity and associated comorbidities

    This study evaluates the effectiveness and safety of a new drug, retatrutide, in individuals with obesity or overweight, including those with knee osteoarthritis or obstructive sleep apnea. Lasting about 89 weeks, the trial involves randomized assignment of participants to either receive retatrutide or a placebo. The main goals are to observe changes in body weight, knee pain in osteoarthritis, and sleep apnea severity. The study also examines various secondary outcomes like changes in BMI, waist circumference, and blood pressure. The trial aims to provide new insights into weight management and associated health conditions, offering hope for improved treatments.

    HungaryPolandRomaniaSpainUnited Kingdom
  • Understanding biliary tract cancer treatment with rilvegostomig and chemotherapy

    This study focuses on a new treatment for biliary tract cancer using the drug rilvegostomig combined with chemotherapy. It is for patients who have had surgery to remove this cancer. The study will compare the effectiveness of rilvegostomig with a placebo in combination with investigator’s choice of chemotherapy options like capecitabine, gemcitabine/cisplatin, or S-1. The main aim is to see if this new treatment can prevent cancer from coming back. About 750 people will take part in this global study, which is in the final phase of testing.

    BelgiumDenmarkGermanyItalyNorwayPolandSpainUnited Kingdom
  • Study of the effectiveness of tanimilast in the treatment of pulmonary diseases

    A 52-week clinical trial is being conducted to investigate the effectiveness and safety of the new drug, known as Tanimilast (CHF6001), in people diagnosed with chronic bronchitis and chronic obstructive pulmonary disease (COPD). The primary aim of the study is to determine the effectiveness of CHF6001 administered as an addition to a standard COPD treatment regimen. Study participants will be randomly assigned to receive the study drug CHF6001 or a placebo, which will be taken concurrently with their existing COPD therapy. Key measurements in the study include monitoring the frequency and severity of COPD exacerbations, which are episodes of significantly worsening symptoms. Additionally, the study will assess changes in participants’ lung function and overall quality of life. Typically eligible for the study are adults who are 40 years of age or older, have a documented history of COPD and chronic bronchitis, and are current or former smokers. In particular, the study is of interest to people who have experienced at least one COPD exacerbation in the year preceding the study.

    AustriaBulgariaCzechiaGermanyGreeceHungaryNetherlandsPolandRomaniaSlovakiaSpainUnited Kingdom
  • Testing new medicine for resistant high blood pressure

    In this 20-week trial, the effectiveness, safety, and optimal dosage of a medication known as XXB750 are being evaluated in individuals with resistant high blood pressure (resistant hypertension). This condition persists despite the use of three different blood pressure medications. XXB750 will be administered through subcutaneous injections, and its efficacy will be compared to a placebo. A 2-week preparation period precedes the trial, during which participants receive three doses of the actual trial medicine and one dose as part of the preparation. Following the trial, participants will be monitored for an additional 8 weeks without receiving any trial medicine during this period. The primary focus is on assessing whether XXB750 can effectively reduce blood pressure when measured over a 24-hour period.

    AustriaBulgariaCzechiaFranceGermanyItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Evaluating the efficacy of macitentan in the treatment of high pulmonary artery blood pressure

    This study is checking if a 75 mg dose of a medicine called Macitentan can do a better job for patients with a lung condition called Pulmonary Arterial Hypertension (PAH) compared to a 10 mg dose. The main goal is to see if the 75 mg dose can better delay the patient’s first major health event related to PAH. Major events include things like unplanned hospital stays related to PAH, or their PAH getting worse. The researchers will check if patients’ PAH gets worse by looking at things like their physical exercise ability and signs of heart failure. The study also looks at how patients’ symptoms change from day to day.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalSlovakiaSpainSwedenUnited Kingdom
  • Testing gefurilimab treatment in patients with myasthenia gravis

    This study is looking at a potential treatment for a disease called generalized myasthenia gravis (gMG) in adults. It’s called gefurulimab (ALXN1720). For our study, researchers will divide participants into two groups, each of which will be treated differently. One group will receive the new drug. Importantly, the researchers conducting the study will not know who received which treatment. This ensures the fairness and accuracy of the results. Participants’ health will be closely monitored to ensure that ALXN1720 is safe. The main goal is to check whether new mediations are effective. It will be measured by checking whether patients’ condition has improved compared to when the study started. This will take approximately 26 weeks.

    AustriaDenmarkFranceGermanyItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Study on the impact of tavapadon on Parkinson’s disease

    This trial is designed to assess a potential treatment for early Parkinson’s disease known as tavapadon. The study spans 27 weeks, during which participants will receive either the actual drug or a placebo (substances without pharmacological effect) in a randomized manner, with neither the individuals nor the researchers knowing who receives which. Parkinson’s disease symptoms will be monitored using a 0-4 scale, where 0 indicates normal and 4 reflects severe impairment across various aspects of daily living and movement. Both the doctor and the participant will assess and score the symptoms and improvements.

    The trial will also include an evaluation of the participant’s personal assessment of change since the start of treatment. Respondents will indicate how much their condition has changed, ranging from very much improved to very much worse. Researchers will additionally examine situations where the participant may feel sleepy, such as reading or sitting in a car for an extended period without a break, scoring between 0 and 3 based on the likelihood of dozing off. The study will monitor potential impulse control disorders, and any side effects or health issues attributable to the treatment.

    FranceGermanyHungaryItalyPolandSpain
  • Testing Nipocalimab’s effect on adults with Muscle Weakness

    This study is about a new drug called nipocalimab for patients with a disease called Myasthenia Gravis (MG). MG patients feel weak in their muscles, and nipocalimab potentially could help to lessen this weakness. The drug functions by attaching itself to certain components of the blood to lessen the reaction causing muscle weakness. This large-scale study will take place in multiple hospitals and is organized in different phases including initial checks (4 weeks), treatment (24 weeks) and follow-ups (up to 2 years). It will be measured how well the treatment works through daily activity scores and strength tests.

    BelgiumCzechiaDenmarkFranceGermanyItalyPolandSpainSweden
  • Study of vaccine combinations against Escherichia coli

    This clinical study is for two vaccines, one protects against a type of bacteria called Escherichia coli (ExPEC9V) and the other is a high-strength flu vaccine. The investigation seeks to determine the effectiveness of administering both vaccines simultaneously compared to separate administrations. The assessment will focus on evaluating immune responses to understand how the body reacts to the vaccines. Additionally, the study aims to identify potential side effects, both at the injection site and elsewhere in the body, caused by the vaccines. Following the administration of shots, participants are required to document any reactions in a diary for 14 days. Subsequent follow-up visits, scheduled 29 days after each shot, will involve repeating tests to assess immune response and reporting any new side effects. The primary interest lies in identifying whether there were any hospital visits related to side effects.

    BelgiumPoland
  • Comparing the effectiveness of two treatments for severe nasal polyps and asthma

    This study is looking at two medications, called Dupilumab and Omalizumab, to see how well they work in people who have severe nose and sinus problems alongside asthma. The main goal is to see if Dupilumab is better at shrinking nasal polyps (small growths in the nose) and improving the sense of smell. Other goals include seeing if Dupilumab can improve symptoms, lung function, and overall health-related quality of life better than Omalizumab. The study also aims to understand how these drugs affect the severity of the disease and asthma control, and their safety. To assess all these, doctors will use various tests, like measuring the size of nasal polyps, testing the ability to smell, and how well one’s lungs are working. Participants in the study will be involved for 38 weeks.

    BelgiumCzechiaDenmarkFinlandFranceGermanyHungaryItalyPolandPortugalRomaniaSpainSwedenUnited Kingdom
  • Comparing treatments in multiple myeloma: talquetamab in combination with other medication

    This study aims to explore the combined effects of talquetamab, daratumumab, pomalidomide, and dexamethasone for treating relapsed or refractory multiple myeloma. One group of patients will receive talquetamab subcutaneous in combination with daratumumab and pomalidomide. The second group will receive talquetamab subcutaneous in combination with daratumumab. The patients of the third group will be treated with daratumumab subcutaneous in combination with pomalidomide and dexamethasone. The research is divided into three phases: screening, treatment, and post-treatment follow-up. The study will assess efficacy, safety, and monitoring various health indicators at specific time points. The results of this combination therapy will be compared to choose the safest and the most effective treatment. The overall duration of the study is expected to be up to 6 years and 6 months.

    BelgiumCzechiaFranceGermanyGreeceItalyNetherlandsPolandSpainUnited Kingdom
  • Testing oral ozanimod for active Crohn’s Disease treatment

    This trial is for a medicine called Ozanimod, that’s taken by mouth. It’s a Phase 3 trial, meaning it’s been tested in smaller trials before and looks promising. The disease we’re looking at is Crohn’s Disease, which can be quite severe. The goal of this trial is to see if Ozanimod can help get the disease under control, this is called an ‘induction therapy’. To make sure the results are accurate, some people will get the real medication while others will get a ‘placebo’, which looks the same but doesn’t have any medicine in it. Everything is double-checked to make sure it’s fair and unbiased.

    BulgariaCzechiaFranceItalyPolandUnited Kingdom
  • Examining new medications for myelofibrosis

    This study is about understanding how two drugs, Navtemadlin (KRT-232) and TL-895, may help patients who have not yet started treatment for a blood condition called Myelofibrosis (MF). It consists of two parts: the first part will look at how safe the drugs are, and how well they can control the disease. Some patients will get Navtemadlin, while others will get TL-895. If the first stage shows promising results, more patients will be enrolled in the second stage to receive one or both of these treatments.

    BulgariaPoland
  • Continued study of ozanimod for severe Crohn’s Disease

    This research is about an extended study on the use of an oral medication named Ozanimod for people suffering from Crohn’s disease. Crohn’s disease can make the stomach and intestines really uncomfortable, causing swellings and pain. The main aim of this study is to check if this medicine, Ozanimod, is safe for intake and how effective it is in easing these uncomfortable feelings in the stomach. The researchers will rate patients’ illnesses using the Crohn’s Disease Activity Index (a measurement tool).

    BelgiumBulgariaCzechiaFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Long-term study on the effectiveness of mirikizumab for Crohn’s Disease

    This research study is about a long-term test of a medicine called Mirikizumab for people who have Crohn’s disease. The main aim of this study is to know if the medicine is effective and safe for those people eventually. The effect of the medicine will be checked using different tests and scores like the Simple Endoscopic Score for Crohn’s Disease, the Crohn’s Disease Activity Index, and patient-reported outcomes. Researchers will also be checking changes in certain markers in the blood and stool that can show inflammation.

    BelgiumCzechiaGermanyHungaryItalyPolandRomaniaSlovakiaSpainUnited Kingdom
  • Studying ozanimod as ongoing treatment for Severe Crohn’s Disease

    This trial is to test a medication called Ozanimod on people who have a serious type of Crohn’s Disease. Crohn’s Disease can make the stomach hurt a lot and sometimes makes difficulty eating.  The researchers want to see if the medication helps to calm the disease, so patients feel better. Some patients will get the Ozanimod and others will get a placebo.  The researchers use  ‘Crohn’s Disease Activity Index’ to see how the disease is doing.

    BelgiumBulgariaCzechiaFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Testing mavacamten for heart muscle disease

    This study aims to assess a drug called Mavacamten for a heart condition called Non-Obstructive Hypertrophic Cardiomyopathy. Patients will be randomly given either the actual drug or a placebo without anyone knowing which one they’ve received. The study will measure how safe and effective the drug is for patients with symptoms of this heart condition. The success of the drug will be determined by preventing heart-related issues such as heart attacks, strokes, heart failures, irregular heartbeats, and the need for a heart-rhythm controlling device.

    AustriaBelgiumCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsNorwayPolandPortugalSpainUnited Kingdom

See more clinical trials in other cities in Poland:

.